hrs4r
 I want to donate

NÚRIA SALA GONZÁLEZ

Firma
NÚRIA SALA-GONZÁLEZ
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Publicacions

Sabaté-Ortega, J, Albert-Carrasco, M, Escribano-Ferrer, C, Grau-Manrubia, G, Fina-Planas, C, López-Núnez, C, Teixidor-Vilà, E, Bujons-Buscarons, E, Montañés-Ferrer, C, Sala-González, N

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Frontiers in oncology, 2024, 14 dx.doi.org/10.3389/fonc.2024.1354127
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41, 3839-3850 dx.doi.org/10.1200/JCO.23.00233
Sabaté Ortega J, Fort Culillas R, Escoda Garcia M, Vásquez-Dongo CA, Sala González N

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

CURRENT ONCOLOGY, 2023, 30, 7802-7809 dx.doi.org/10.3390/curroncol30090566
Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration- resistant prostate cancer: a randomised, double-blind, phase 2 trial

LANCET ONCOLOGY, 2022, 23, 1297-1307 dx.doi.org/10.1016/S1470-2045(22)00498-3
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13225830
España S, Ochoa de Olza M, Sala N, Piulats JM, Ferrandiz U, Etxaniz O, Heras L, Buisan O, Pardo JC, Suarez JF, Barretina P, Comet J, Garcia Del Muro X, Sumoy L, Font A

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate

Cancer Management and Research, 2020, 12, 10251-10260 dx.doi.org/10.2147/CMAR.S270392
Jiménez N, Reig Ò, Montalbo R, Milà-Guasch M, Nadal-Dieste L, Castellano G, Lozano JJ, Victoria I, Font A, Rodriguez-Vida A, Carles J, Suárez C, Domènech M, Sala-González N, Fernández PL, Rodríguez-Carunchio L, Díaz S, Prat A, Marín-Aguilera M, Mellado B

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer

Frontiers in oncology, 2020, 10, 594023-594023 dx.doi.org/10.3389/fonc.2020.594023
Puente J, González-Del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez Á, Cuevas Sanz JM, Muñoz Del Toro JR, Useros Rodríguez E, García García-Porrero Á, Vázquez S

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Bmc Cancer, 2019, 19, 766-766 dx.doi.org/10.1186/s12885-019-5974-9
Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

LANCET ONCOLOGY, 2018, 19, 975-986 dx.doi.org/10.1016/S1470-2045(18)30365-6
Suárez C, Campayo M, Bastús R, Castillo S, Etxanitz O, Guix M, Sala N, Gallardo E

Prognostic and Predictive Factors for Renal Cell Carcinoma

TARGETED ONCOLOGY, 2018, 13, 309-331 dx.doi.org/10.1007/s11523-018-0557-2

Formulari de contacte

About IDIBGI!

menu